MAPT and tauopathy: Although much effort has gone into characterizing the natural history and longitudinal declines of MAPT pathogenic variant carriers (reviewed in [6]), we understand relatively little about the molecular mechanisms that impart risk for sporadic forms of tauopathy—whether primary or secondary.